David U’Prichard has been elected by stockholders to the board of directors of Invitrogen, effective April 29, 2004. U’Prichard is a venture partner with Apax Partners and is president of Druid Consulting, a pharma and biotech consulting firm. Prior to these positions, U’Prichard was CEO of 3-Dimensional Pharmaceuticals. Prior to that, he served as chairman of R&D at SmithKline Beecham. He has also had various positions at ICI/Zeneca. In addition, he has previously held academic appointments at Northwestern University Medical School, Johns Hopkins University, University of Maryland, and the University of Pennsylvania. U’Prichard holds a bachelor’s degree in pharmacology from the University of Glasgow, and a PhD in pharmacology from the University of Kansas.
David McCarty will leave the board after serving on it for five years. McCarty was president and CEO of Novex when the company was acquired by Invitrogen in 1999.
Michael Tognotti has joined CombiMatrix of Mukilteo, Wash., as director of sales in North America for the company’s CustomArray line of microarrays. CombiMatrix is the life sciences unit of Acacia Research. Tognotti’s responsibilities include building and managing sales, technical support, and customer services for the product. Previously, Tognotti was in sales and marketing management positions at San Diego-based Illumina. He has previously worked for Qiagen, Fisher Scientific, and Genentech.